TBUFF News Alert Tribute Pharmaceuticals Canada Inc. (TBUFF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.4600 $TBUFF

Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST


Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:29AM CST


Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST


Tribute Pharmaceuticals to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
MILTON, ON / ACCESSWIRE / November 7, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TRX.V) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 11:00 AM Eastern Time.

Tribute Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:47PM CST


CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 10:49AM CST
This release corrects and replaces the press release sent on November 3 at 10:26 AM ET for Tribute Pharmaceuticals Canada Inc. In the first paragraph, "second quarter ending September 30, 2014" has been changed to "third quarter ending September 30, 2014". The corrected version follows.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 9:26AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, November 10, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending September 30, 2014.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe
Marketwired - Thu Oct 30, 7:41AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , today announced that it has received a patent approval from the European Patent Office ("EPO" for intellectual property central to one of the Company's lead products, Uracyst(R)/Uropol(R) (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG" deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation- induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulfate in an amount of at least 400 mgs and an aqueous vehicle. This patent will run until February 18, 2024.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R)
Marketwire - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide®
Marketwire Canada - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company" , is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products" from Novartis AG ("Novartis" for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States
Marketwire - Thu Sep 25, 8:20AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , today announced that it has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central to one of the Company's lead products, Uracyst(R) (a sterile sodium chondroitin sulfate solution, 2%, which is used in the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS" ).
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results
Marketwire - Mon Aug 11, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014
ACCESSWIRE - Fri Aug 08, 3:26PM CDT
MILTON, ONTARIO / ACCESSWIRE / August 8, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.
TRX.VN: 0.560 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 34

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 36

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 5

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 70

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 20

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 60

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 83

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 54

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 55

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Maximizing Your Retirement with $1 Million

Updated Category News Views 148

Planning for a Comfortable Retirement with $1 Million Reaching the milestone of having $1 million saved in your IRA as you near your 70th birthday is a commendable accomplishment. However, to make sure this amount lasts throughout your retirement, which could extend over two decades, careful planning is essential. Effectively managing your retirement funds requires a good...

Continue Reading
Wells Fargo Downgrades SailPoint to Equalweight: What It Means

Updated Category News Views 116

Wells Fargo Downgrades SailPoint Technologies Holdings Wells Fargo has recently revised its stance on SailPoint Technologies Holdings (NYSE: SAIL), changing its investment rating from Overweight to Equalweight. Alongside this rating downgrade, the bank has also lowered its price target for the stock from $17 to $15. This shift indicates a more reserved outlook on the...

Continue Reading
Brunswick Exploration's Promising Lithium Recovery Results

Updated Category News Views 120

Promising Phase 1 Metallurgical Results from Brunswick Exploration Brunswick Exploration Inc. (TSX-V: BRW; OTCQB: BRWXF; Frankfurt: 1XQ) has exciting developments regarding its Mirage Project. The Montreal-based mineral exploration company is charting a significant course in extracting lithium through innovative methodologies. Recent preliminary metallurgical results from...

Continue Reading
Enhancing Bone Health: A New Partnership in Australia

Updated Category News Views 174

The Global Healthy Living Foundation Australia (GHLF Australia) forged a partnership with The Bone Bus back then, aiming to pump up bone health access in rural spots where folks were really struggling. This initiative wasn't just some PR stunt; it targeted real issues surrounding osteoporosis that so many older Australians faced. Rural Access: A Tough Nut to Crack Let’s...

Continue Reading
Kotak Securities Revises Target for Larsen & Toubro, Maintains Sell Rating

Updated Category News Views 176

Kotak Securities slammed the brakes on any bullish sentiment around Larsen & Toubro Ltd. (LT:IN) back in late 2024, despite raising their price target from INR3,150 to INR3,380. Now, this sounds like good news on paper—a bit of upward adjustment—but let’s not kid ourselves here. They slapped a Sell rating on it right alongside that shiny new number. What gives?...

Continue Reading